The efficacy and safety of once-daily beclomethasone dipropionate (BDP; 200 µg), in combination with the propellant hydrofluoroalkane-134a (HFA) was compared with that of budesonide turbuhaler (BUD-TH) 400 µg twice daily and fluticasone propionate inhaler (FP-IH) 250 µg twice daily in 40 patients with bronchial asthma or chronic obstructive pulmonary disease. All patients had used inhaled corticosteroids for at least 1 month. On randomization, 20 patients were switched to HFA-BDP and 20 patients remained on their existing BUD-TH or FP-IH treatment. After 8 weeks, HFA-BDP demonstrated a greater improvement in spirometric values, respiratory symptoms and β 2 -agonist use. No significant local adverse effects were observed. Blood cortisol levels remained in the normal range in both groups. We conclude that HFA-BDP (200 µg once-daily) offered more benefit in terms of clinical and spirometry indices than BUD-TH (400 µg twice daily) or FP-IH (250 µg twice daily) in patients with moderate asthma and chronic obstructive pulmonary disease.
Introduction
The mandatory replacement of chlorofluorocarbons (CFCs) in pressurized metered-dose inhalers (MDIs) with nonozone-depleting substances 1 has led to the development of alternative propellants. The introduction of hydrofluoroalkane-134a (HFA) has demonstrated that this alternative propellant has additional advantages. Beclomethasone dipropionate (BDP), an established inhaled corticosteroid for the treatment of asthma, has been reformulated using HFA as the propellant. This new combination constitutes a solution, rather than a suspension and, as the propellant evaporates, an extra fine aerosol of small droplets is formed. The mass median aerodynamic diameter (MMAD) of HFA-BDP is 1.1 µg (and even less with the autohaler device) and 60% of the particles are in the G Tatsis, K Kotsifas, V Filaditaki et al. Beclomethasone dipropionate for asthma and COPD respiratory range, as compared with an MMAD of 3.5 -4 µg and 25% of the particles being in the respiratory range for CFC-based preparations. 2 -4 Scintigraphic studies, in healthy volunteers as well as in patients with asthma, have shown HFA-BDP to have better deposition in the lungs and less deposition in the oropharynx, compared with CFC-BDP. 5, 6 Subsequent studies have demonstrated the clinical efficacy of HFA-BDP versus placebo in steroid-naïve patients, 7, 8 and in comparison with already existing substances and formulations. For example, half of the dose of HFA-BDP was as equally effective as conventional CFC-BDP 9 -12 and budesonide turbuhaler (BUD-TH), 13, 14 whereas a dose equivalence was shown when compared with CFC-fluticasone. 15 HFA-BDP (800 µg) has also been shown to be as equally effective as HFA-fluticasone (1000 µg) in patients with moderate-tosevere asthma. 16 The exact dose equivalence of HFA-BDP and CFC-BDP has not been fully established. 17 A 2.6 -3.2:1 relationship has been supported by a well-conducted clinical trial, 10 which is modest compared with a 10-fold difference in lung deposition from scintigraphic studies. 5, 6 However, most trials have used a 2:1 dose ratio. 9 -12 Among the various formulations of HFA-BDP, the most widely studied and used is Qvar™ (3M Pharmaceuticals, St Paul's, MN, USA), which is available in a 'press and breathe' inhaler as well as an autohaler. We used the autohaler device in this study. An informative review of HFA-BDP delivered by various devices has been published recently. 17 The possibility of once-daily administration of inhaled corticosteroids is a very important issue. A considerable body of evidence supports this frequency of dosing, which would result in obvious advantages in terms of convenience for the patient and improved compliance. 18 To date, once-daily dosing of HFA-BDP has not been studied.
The role of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD) remains controversial, 19, 20 Current guidelines apply to pure COPD patients and recommend them for patients with moderate to severe obstruction (FEV 1 < 50%) and frequent exacerbations 21 yet, in clinical practice, they are more widely prescribed. On the other hand, those COPD patients with reversible obstruction, in whom we would expect greater benefit are usually excluded from clinical trials. Studies on HFA-BDP in COPD patients are now making an appearance in the literature. 22, 23 In this 8-week randomized study, we examined the clinical efficacy, acceptance and safety of low-dose HFA-BDP administered once daily by an autohaler device (Qvar™) compared with an established twice-daily medium-dose of budesonide turbuhaler (Pulmicort Turbuhaler™, Astra, Sweden) (BUD-TH) or fluticasone propionate inhaler (Flixotide Inhaler™, GlaxoSmithKline, UK) (FP-IH) in patients with bronchial asthma or chronic obstructive pulmonary disease (COPD) with an asthmatic component.
Patients and methods

PATIENT POPULATION
Patients over 18 years old were recruited to the study. A diagnosis of bronchial asthma or COPD was established by history, clinical examination and spirometry. COPD patients were required to have an asthmatic component, supported by a 15% improvement in forced expiratory volume in 1 s (FEV 1 ) or forced vital capacity (FVC) after β 2 -agonist inhalation. Patients were required to have had respiratory symptoms during the last 4 weeks that were of moderate G Tatsis, K Kotsifas, V Filaditaki et al. Beclomethasone dipropionate for asthma and COPD severity, according to GINA and GOLD guidelines. 21, 24 Meanwhile they were required to be clinically stable during this time period, not suffer from any respiratory infections and not receive any steroids other than inhaled preparations. Patients with serious or unstable concomitant diseases were excluded. Previous treatment included either BUD-TH 400 µg twice daily or FP-IH 250 µg twice daily.
This study gained approval by the Ethical Committee of Evangelismos General Hospital and all patients gave written informed consent to participate. The study was performed in accordance with the ethical principles outlined in the Helsinki Declaration.
STUDY TREATMENT
On day 0, patients were randomized to receive either BDP-HFA 200 µg once daily or to remain on their existing treatment of either BUD-TH or FP-IH (control group). The use of additional medication was recorded and left unchanged, while the use of salbutamol (Salbunova Autohaler™, 3M Pharmaceuticals) as a reliever was recorded. The inhalation technique for each device was meticulously demonstrated by the investigators.
PATIENT ASSESSMENT
Patients were assessed on days 0, 28 and 56. At each visit, spirometry was performed and respiratory questionnaires were completed.
Patients were asked about the frequency and severity of dyspnoea, cough, sputum production, sputum colour, and the frequency of daily salbutamol use. Respiratory symptoms were recorded according to the following scales: dyspnoea: 0, without any dyspnoea; 1, dyspnoea on moderate exertion; 2, dyspnoea on mild exertion; 3, dyspnoea on minimum exertion; 4, mild to moderate dyspnoea at rest; 5, severe dyspnoea at rest; cough: 0, no cough; 1, mild cough; 2, moderate cough; 3, severe cough; sputum production: 0, none; 1, mild, 2, moderate, 3, large amount; sputum colour: 0, colourless; 1, white/grey; 2, light yellow/green; 3, deep yellow/green. Compliance was assessed by questionnaire. No more than four missed doses per month were accepted, otherwise the patient would be excluded from the study and the analysis. A morning blood sample was collected for the assessment of blood cortisol levels. At the end of the study, patients were asked whether their symptoms had been ameliorated by treatment and how easy their inhaler device was to use. It was not possible to blind patients and physicians to the treatment.
STATISTICAL ANALYSIS
Distribution of the qualitative variables of the study (e.g. gender) between the groups are presented as frequencies, while distribution of the quantitative variables (e.g. age) are given as the mean ± SD.
The homogeneity of the two treatment groups at baseline was tested using the χ 2 test for gender, personal respiratory history and hospitalizations due to exacerbations (yes/no). The Student's t-test was used for weight and height, spirometric results (FVC observed and percentage predicted, FEV 1 observed and percentage predicted), the frequency of daily salbutamol use, and blood cortisol levels. For each separate treatment group, the variation of the mean values of the spirometric parameters %FVC and %FEV 1 predicted at each study visit was tested using the statistical technique of repeated measures analysis of variance (Wilks' lambda statistic). The same techniques (repeated measures analysis of variance and independent samples t-test) were also used G Tatsis, K Kotsifas, V Filaditaki et al.
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for the frequency of daily salbutamol use.
The Mann-Whitney non-parametric test was used to analyse patients' assessment of their overall improvement of symptoms by the end of the study and the convenience of using inhaler devices.
For blood cortisol levels, the dependent samples t-test was used in each treatment group separately in order to compare mean baseline and final visit values. In addition, the mean difference between the baseline and final consultation values was calculated. The difference between the treatment groups was compared using the independent samples t-test. For all of the tests described, P < 0.05 was considered significant.
Results
STUDY POPULATION
Forty patients were included in the study. Fourteen had bronchial asthma of moderate severity and 26 had COPD of moderate severity, in accordance with GINA and GOLD guidelines, respectively. 21, 24 The main clinical features of the study population at baseline are shown in Table 1 .
On randomization, 20 patients entered the HFA-BDP group, while 20 patients remained on their previous treatment (control group) ( Tables 2 and 3 ). Any additional treatment already being used before the study commenced was left unchanged. At study entry, age, gender, personal respiratory history, spirometric results, vital signs, frequency of daily salbutamol use, respiratory symptoms and blood cortisol levels were not statistically different between the two groups.
COMPLIANCE
No patient withdrew from the study. In order to assess the acceptance of the autohaler device, at the end of the study patients in both groups were asked whether they found 'their device easy to use' and whether they 'liked the device'. For both questions, the HFA-BDP autohaler device was rated significantly higher than the control group inhalers: 100% of the HFA-BDP group found the device very easy to use compared with 75% of the control group; and 95% of patients in the HFA-BDP group expressed full acceptance of the autohaler device compared with 55% of the control group (Figs 1 and 2) . The results of the statistical analyses were: 'easy to use': Mann-Whitney U statistic = 150.0, Wilcoxon W statistic = 360.0, Z statistic = -2.4, P = 0.018; 'overall satisfaction': Mann-Whitney U statistic = 120.0, Wilcoxon W statistic = 330.0, Z statistic = -2.9 (P < 0.001).
SPIROMETRY
In both groups the mean values of %FEV 1 and %FVC gradually increased at each study visit and were statistically significant in both groups compared with baseline, as determined by repeat measures analysis of variance (HFA-BDP group: Wilks' lambda F statistic = 24.14, df = 18, P < 0.001; control group: Wilks' lambda F statistic = 23.25, df = 18, P < 0.001). The increase in the HFA-BDP group was significantly greater than in the control group (P < 0.05, see below). More specifically, on day 28, in the HFA-BDP group, the mean increase of %FVC predicted from baseline was 6.3 ± 5.9% compared with a mean increase in the control group of 3.0 ± 2.0% (two independent samples t-statistic = 2.32, df = 38, P = 0.026); and on day 56, the mean increase of %FVC predicted from baseline in the HFA-BDP group was 12. (Table 4) .
Similarly, on day 28, the mean increase of %FEV 1 predicted from baseline, in the HFA-BDP group was 9.0 ± 6.2% compared with a mean increase in the control group of 3.3 ± 3.3% (two independent samples t-statistic = 3.72, df = 38, P = 0.001); and on day 56, the mean increase of %FEV 1 predicted from baseline in the HFA-BDP .8% compared with a mean increase in the control group of 6.1 ± 6.0% (two independent samples t-statistic = 4.21, df = 38, P < 0.001) ( Table 5 ).
RESPIRATORY SYMPTOMS
Respiratory symptoms (dyspnoea, cough, sputum production, sputum colour) are shown in Table 6 . These symptoms improved during the study in both groups; again, this improvement was greater in the intervention group and the difference was statistically significant (P < 0.005).
In answer to the question 'after 2 months of treatment, how would you describe any change in your symptoms', 90% of the HFA-BDP group reported a 'great improvement' compared with 25% of the control group (Fig. 3) . This difference was also statistically significant (Mann-Whitney U statistic = 66.0, Wilcoxon W statistic = 276.0, Z statistic = -4.1, P < 0.001).
β2-AGONIST USE
In both treatment groups, the frequency of daily salbutamol use decreased between the first and third visits (although it did not decrease between the first and second visits in the control group) ( Table 7 ). This decrease was statistically significant, using repeated measures analysis of variance, in both groups (HFA-BDP group: Wilks' lambda F statistic = 35.00, df = 18, P < 0.001; control group: Wilks' lambda F statistic = 11.76, df = 18, P = 0.001). The decrease in daily salbutamol use was greater in the HFA-BDP group compared with the control group (P < 0.05, see below).
More specifically on the second visit (day 28) the mean decrease in the frequency of daily salbutamol use compared with baseline in the HFA-BDP group was 0.5 ± 0.7% compared with a mean decrease in the control group of < 0.1 ± 0.7% (two independent samples t-statistic = 2.32, df = 38, P = 0.026); and on the third visit (day 56), the mean decrease in the frequency of daily salbutamol use compared with baseline in the HFA-BDP group was 1.5 ± 0.9% compared with a mean decrease in the control group of 0.6 ± 0.6% (two independent samples t-statistic = 2.79, df = 38, P = 0.008).
SAFETY
No significant local adverse events, especially oral candidiasis or voice changes, were noted. Regarding the systemic action of the inhaled corticosteroids, the mean morning blood cortisol levels on day 0 were 13.0 µg/dl in the HFA-BDP group and 13.2 µg/dl in the control group. No significant change was recorded in the HFA-BDP group, while levels increased slightly in the control group (paired samples G Tatsis, K Kotsifas, V Filaditaki et al. Beclomethasone dipropionate for asthma and COPD t-statistic = 6.1, df = 19, P < 0.001). The mean increase in blood cortisol levels in the HFA-BDP group was 0.04 ± 0.8 µg/dl compared with a mean increase in the control group of 1.5 ± 1.1 µg/dl (two independent samples t-statistic = 4.79, df = 38, P < 0.001) ( Table 8 ).
Discussion
In this study we compared once-daily lowdose HFA-BDP (200 µg) with twice-daily medium-dose BUD-TH (400 µg) and FP-IH (250 µg) in patients with asthma or COPD of moderate severity.
The study demonstrated that HFA-BDP was slightly more efficacious in improving classic spirometric indices and respiratory symptoms than the control inhalers.
The most interesting finding of this study was that the low dose of inhaled corticosteroids (i.e. 200 µg of HFA-BDP) was shown to be more effective than a medium dose of a more traditional one (i.e. 500 µg FP-IH and 800 µg BUD-TH). A dose ratio of 1:2.5 and 1:4 has not been studied previously, although the exact dose equivalence is not known and it could theoretically be lower than what has been tested in clinical trials to date.
Once-daily administration of inhaled corticosteroids has been proposed to be as equally effective as multiple doses. 18 Compliance in our study, as assessed by a patient questionnaire, was very good in both treatment groups, while effectiveness of once-daily HFA-BDP was maintained.
A second important issue that impacts on the efficacy of any asthma treatment is the simplicity of the inhaler device that is used. The HFA-BDP autohaler does not require coordination, as is required for classic 'press and breathe' inhalers, or high inspiratory flows, as required by the turbo inhalers. 4 We believe that this simple advantage is reflected in the improved clinical and spirometric indices, as well as by the general acceptance of the HFA-BDP device.
A small but significant improvement in the spirometric indices and respiratory symptom scores was noted in the control group, despite the fact that treatment did not change. Better compliance to treatment due to closer medical supervision, as well as re-education on the proper use of their devices, might explain this result.
Considerable controversy exists as to the role of corticosteroids in COPD. 19, 20 Although frequently prescribed, inhaled corticosteroids are not expected to alter the natural history of COPD and are not generally recommended by formal guidelines for the treatment of moderate COPD. 21 However, studies that have examined the role of inhaled corticosteroids in COPD have systematically excluded patients that responded to bronchodilation, in other words those patients that could theoretically benefit from inhaled corticosteroid 19 Furthermore, recent evidence suggests a systemic anti-inflammatory action of low-dose inhaled corticosteroids in pure COPD patients, which is reflected in a significant reduction in mortality. 25, 26 Thus, inhaled steroids in COPD remain a controversial issue and their role may be reconsidered in the near future.
In this study, we could not separate patients with COPD and asthma as there were insufficient patient numbers for statistical analysis. However, we believe that treating COPD patients that have an asthma component to their disease with inhaled steroids is both rational and beneficial for them. Similarly, the patient numbers were insufficient to allow separate comparisons between HFA-BDP and either BUD-TH or FP-IH.
In clinical studies, HFA-BDP has been shown to be safe in conventional doses, demonstrating no increase in local 27, 28 or systemic side-effects. 29 In our study, no local complications were noted in either treatment groups. Again, improved patient education, the low-to-medium dose of treatment and, perhaps, the relatively small number of participants, may explain this result.
In contrast, morning blood cortisol levels were increased slightly in the control group, possibly suggesting a less systemic action. Though statistically significant, this difference was small and probably of minor clinical importance, as cortisol levels remained in the normal range. The systemic action of the study treatments was not a primary endpoint of the study and it should be noted that measuring morning blood cortisol levels is a simple method, but it is not accurate enough to evaluate the effects of these agents on the hypothalamic pituitary adrenal axis. 30 A possible placebo effect, especially when patients completed their questionnaires, also cannot be excluded; patients knew whether they had switched to a new drug and device because we were not able to provide a unique device for the different drugs and formulations. In addition, it would have been unethical to leave symptomatic patients without treatment. Overall, we believe that our study included patients that more realistically represented those treated in everyday clinical practice and our results suggest that once-daily HFA-BDP warrants further evaluation in a larger patient group.
We conclude that this small pilot study of patients with moderate asthma and COPD demonstrated that once-daily HFA-BDP (200 µg) offered more benefit in terms of clinical and spirometry indices than BUD-TH (400 µg twice daily) or FP-IH (250 µg twice daily). Patients commented favourably on both the convenience and effectiveness of the new once-daily HFA-BDP autohaler device, and no clinically important safety issues were observed.
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